Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Central Nervous System
  4. Back
  5. Myasthenia
  6. Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome, medicines that may affect patients (642)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome, medicines that may affect patients (642)

Warning

There are certain medicines that have been reported to worsen or induce myasthenia gravis (MG), often by increasing muscular weakness, and should be used with caution in patients with this condition. The list of medicines in table 1 has been compiled to assist prescribers in the decision making process when prescribing medicines for patients with myasthenia gravis.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 27/04/2022

Next review date: 01/03/2025

Author(s): Laura Stobo.

Version: 2

Author email(s): laura.stobo@ggc.scot.nhs.uk.

Approved By: Medicines Utilisation Subcommittee of ADTC

Reviewer name(s): Laura Stobo.

Document Id: 642